Liontrust Investment Partners LLP Has $101.46 Million Stake in Becton, Dickinson and Company $BDX

Liontrust Investment Partners LLP grew its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 18.0% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 645,308 shares of the medical instruments supplier’s stock after purchasing an additional 98,212 shares during the period. Becton, Dickinson and Company comprises 1.4% of Liontrust Investment Partners LLP’s holdings, making the stock its 20th largest holding. Liontrust Investment Partners LLP’s holdings in Becton, Dickinson and Company were worth $101,462,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Crux Wealth Advisors boosted its stake in shares of Becton, Dickinson and Company by 0.8% in the fourth quarter. Crux Wealth Advisors now owns 6,297 shares of the medical instruments supplier’s stock valued at $1,222,000 after buying an additional 49 shares during the period. Larson Financial Group LLC increased its stake in Becton, Dickinson and Company by 1.7% during the 4th quarter. Larson Financial Group LLC now owns 3,230 shares of the medical instruments supplier’s stock worth $627,000 after acquiring an additional 53 shares during the period. Camelot Portfolios LLC raised its holdings in Becton, Dickinson and Company by 1.5% in the 4th quarter. Camelot Portfolios LLC now owns 3,545 shares of the medical instruments supplier’s stock valued at $688,000 after acquiring an additional 54 shares in the last quarter. McElhenny Sheffield Capital Management LLC lifted its position in shares of Becton, Dickinson and Company by 3.6% during the 4th quarter. McElhenny Sheffield Capital Management LLC now owns 1,590 shares of the medical instruments supplier’s stock valued at $309,000 after acquiring an additional 55 shares during the period. Finally, Atlantic Union Bankshares Corp grew its holdings in shares of Becton, Dickinson and Company by 0.9% during the 4th quarter. Atlantic Union Bankshares Corp now owns 6,108 shares of the medical instruments supplier’s stock worth $1,185,000 after purchasing an additional 57 shares in the last quarter. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Stock Down 1.7%

Shares of BDX opened at $165.59 on Friday. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $187.35. The stock has a market capitalization of $45.63 billion, a price-to-earnings ratio of 41.92, a PEG ratio of 12.00 and a beta of 0.21. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.94. The stock has a fifty day moving average of $151.48 and a 200-day moving average of $163.63.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.13. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The company had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.67 billion. During the same quarter last year, the business posted $3.35 EPS. Becton, Dickinson and Company’s revenue for the quarter was up 5.2% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. As a group, sell-side analysts anticipate that Becton, Dickinson and Company will post 12.53 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be issued a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a dividend yield of 2.5%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s payout ratio is 106.33%.

Insider Activity at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,100 shares of Becton, Dickinson and Company stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the sale, the executive vice president directly owned 13,172 shares in the company, valued at $1,918,633.52. This trade represents a 7.71% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $146.35, for a total transaction of $404,511.40. Following the sale, the chief executive officer directly owned 110,163 shares in the company, valued at $16,122,355.05. The trade was a 2.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 5,189 shares of company stock valued at $765,661 in the last ninety days. 0.40% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on BDX shares. Wells Fargo & Company boosted their price target on Becton, Dickinson and Company from $157.00 to $161.00 and gave the company an “equal weight” rating in a research note on Friday, May 8th. TD Cowen reduced their price objective on shares of Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating on the stock in a research note on Monday, May 4th. Barclays raised their target price on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a report on Monday, May 11th. Bank of America cut their price target on shares of Becton, Dickinson and Company from $177.00 to $170.00 in a report on Friday, June 12th. Finally, The Goldman Sachs Group reduced their price target on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 27th. Eight investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $180.93.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.